Xiling Jiang Selected Research

Bispecific Antibodies

4/2020	Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
8/2018	Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiling Jiang Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 08/2018
2	Diarrhea 01/2021 - 01/2021
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2021
2	Fatigue 01/2021 - 01/2021
2	Experimental Arthritis 04/2016 - 01/2016
2	Rheumatoid Arthritis 01/2016 - 01/2016
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2023
1	Rare Diseases (Rare Disease) 01/2023
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Nausea 01/2021
1	Hemorrhage 01/2021
1	Esophageal Squamous Cell Carcinoma 01/2021
1	Alopecia (Baldness) 01/2021
1	Asthenia 01/2021
1	Esophageal Fistula 01/2021
1	Exanthema (Rash) 01/2021
1	Wilms Tumor (Wilm's Tumor) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Proteinuria 01/2021
1	Stomatitis 01/2021
1	Varicose Veins (Varicose Vein) 01/2021
1	Vomiting 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2020
1	Cytokine Release Syndrome 04/2020
1	Carcinoma (Carcinomatosis) 01/2020
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018

Drug/Important Bio-Agent (IBA)

4	Monoclonal AntibodiesIBA 01/2018 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2018
2	CytokinesIBA 04/2020 - 01/2016
2	Bispecific AntibodiesIBA 04/2020 - 08/2018
2	Interleukin-6 (Interleukin 6)IBA 01/2016 - 01/2016
1	Azacitidine (5 Azacytidine)FDA Link 11/2023
1	ivosidenibIBA 11/2023
1	Transfer RNA (tRNA)IBA 01/2022
1	Hormones (Hormone)IBA 01/2021
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 01/2021
1	Lipase (Acid Lipase)FDA Link 01/2021
1	pertuzumabIBA 01/2021
1	AlpelisibIBA 01/2021
1	Bevacizumab (Avastin)FDA Link 01/2021
1	Trastuzumab (Herceptin)FDA Link 01/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	Fulvestrant (Faslodex)FDA Link 01/2021
1	NivolumabIBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2021
1	CalciumIBA 01/2021
1	CreatinineIBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	atezolizumabIBA 01/2021
1	PlatinumIBA 01/2021
1	TransferasesIBA 01/2021
1	blinatumomabIBA 04/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 08/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Ustekinumab (CNTO 1275)FDA Link 01/2018
1	InterleukinsIBA 01/2018
1	Interleukin-12 (IL 12)IBA 01/2018
1	Interleukin-23 (Interleukin 23)IBA 01/2018
1	EnzymesIBA 01/2016
1	sirukumabIBA 01/2016
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2016

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 01/2021 - 01/2021
1	Therapeutics 01/2023
1	Subcutaneous Injections 01/2021